
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Carole R. Burns, OD, FCOVD, explains how eyewear transitions are positioned in her practice, and why doing so is a necessity for all patients.
The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or MJH Life Sciences.






